Table 1

Demographic and clinical characteristics distributed by diagnosis (n=963)

All patientsDLBCL*
n=154 (16.0%)
Myeloma
n=153 (15.9%)
AML†
n=119 (12.4%)
MDS‡
n=109 (11.3%)
CLL§
n=91 (9.4%)
MPN¶
n=78 (8.1%)
Other
n=259 (26.9%)
Gender
Male (%)549 (57.0)78 (50.6)87 (56.9)66 (55.5)74 (67.9)55 (60.4)39 (50.0)150 (57.9)
Age (years, median IQR)††
At diagnosis75.8 (66.4–82.9)75.0 (64.5–81.5)72.1 (63.6–80.4)76.3 (66.2–83.4)76.1 (68.3–82.2)76.1 (69.8–84.2)80.7 (74.8–87.2)75.9 (66.3–83.4)
At death77.9 (68.6–85.0)75.9 (66.3–83.2)74.6 (66.8–83.3)77.5 (67.6–83.9)77.9 (72.2–83.2)79.5 (73.2–85.9)83.8 (77.9–89.9)78.1 (69.3–85.2)
IMD** category (%)
Most affluent1360 (37.4)59 (38.3)63 (41.2)45 (37.8)44 (40.4)30 (33.3)27 (34.6)92 (35.5)
2319 (33.2)50 (32.5)50 (32.7)39 (32.8)26 (23.9)30 (33.3)31 (39.7)93 (35.9)
Most deprived3283 (29.4)45 (29.2)40 (26.1)35 (29.4)39 (35.8)30 (33.3)20 (25.6)74 (28.6)
Time from diagnosis to death (%)
0–6 months282 (29.3)77 (50.0)40 (26.1)72 (60.5)14 (12.8)14 (15.4)6 (7.7)59 (22.8)
6+ months681 (70.7)77 (50.0)113 (73.9)47 (39.5)95 (87.2)77 (84.6)72 (92.3)200 (77.2)
Median (IQR)17.1 (4.4–42.8)6.2 (1.1–25.8)25.6 (5.6–42.9)3.1 (0.9–14.4)20.4 (8.7–35.4)36.7 (10.7–52.7)39.8 (21.3–55.4)18.0 (7.3–45.4)
Underlying cause of death‡‡
Haematological malignancy (%)655 (68.0)117 (76.0)118 (77.1)107 (89.9)73 (67.0)42 (46.2)21 (26.9)177 (68.3)
Hospital-based SPC referral (n=892)§§
Yes (%)319 (35.8)50 (38.8)61 (42.1)54 (53.5)29 (27.1)29 (32.6)11 (14.1)85 (35.0)
  • *Diffuse large B-cell lymphoma.

  • †Acute myeloid leukaemia.

  • ‡Myelodysplastic syndromes.

  • §Chronic lymphocytic leukaemia.

  • ¶Myeloproliferative neoplasms.

  • **Index of Multiple Deprivation (income domain): one patient with missing data.

  • ††IQR.

  • ‡‡Derived from death certificate data, Medical Research Information Service.

  • §§Specialist palliative care: 71 patients with no data collection due to death within 14 days.